The decline in Merck's share price has increased its dividend yield, making it more attractive to income-focused investors. The strong performance of Keytruda and the potential for further approvals and market expansion enhance Merck's growth prospects. Additionally, Merck's diverse drug portfolio and robust pipeline provide a solid foundation for future growth, making the current valuation appealing.